Skip to content
S4845Senate2009-2010 SessionSame asA8131

Authorizes any city with a population in excess of one million to provide a biotechnology credit against certain taxes

Sponsor Thomas K. DuaneSD-29+5 co-sponsorsAffects Environment & Energy
Status
Senate Floor Calendar
Impact
Pending
Outcome
Companion signed

Bill progress

Signed via A8131

What's happening

Writing a plain-English summary… Track this bill to get it by email.

Why it matters

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

Headline styles

Sponsors

History

  1. Substituted by A8131
  2. Advanced to third reading
  3. 2nd report cal.
  4. 1st report cal.645
  5. Print number 4845b
  6. Amend (t) and recommit to energy and telecommunications
  7. Print number 4845a
  8. Amend and recommit to energy and telecommunications
  9. Referred to energy and telecommunications

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A8131Assembly

Authorizes N.Y. city to provide a biotechnology credit to be taken against the general corporation, unincorporated business and banking taxes

Signed by Governor · Sponsor David Weprin

Signed into law

Full text

The text isn't available here yet. Check nysenate.gov.

Sponsor's memo

Title of bill

An act to amend the tax law, in relation to authorizing any city having a population of one million or more to provide a biotechnology credit against the general corporation tax, unincorporated business tax and banking corporation tax of such city

Summary of specific provisions

This bill would amend Section 1201-a of the tax law by adding a new subdivision (d). In Section 1 of the bill, paragraph 1 of new subdivision (d)would allow New York City to create, by local· law, a credit against the City's general corporation, unincorporated business and banking taxes, substantially identical to New York State's Qualified Emerging Technologies Facilities, Operations and Training Credit, as provided in subdivision 12-g of Section 210 of the tax law. New York City's credit, termed the "Biotechnology Credit" would be limited to companies in biotechnology as defined in Section 3102-e (b) (5) of the public authorities law.

While this credit is substantially identical to the New York State's Qualified Emerging Technologies, Facilities, Operations and Training State credit, this credit differs from the State's credit in several ways.

Read the full memo (905 words)

Paragraph 2 establishes a two-tiered credit. In the first tier, eligible firms will receive 100% of the credit available, up to $250,000 per calendar year. Firms will be eligible for this tier of the credit if firms increase their employment level by 5% more than their employment level in their base year. Firms that are newly established, newly relocated, or did not have any employees in the year prior to which the credit is claimed are not subject to the base year employment increase, are eligible this tier of the credit. In the second tier, firms who increase their employment level by less than 5% of their base year employment, the maximum amount of the credit will be 50% of the maximum amount of the credit, not to exceed $125,000. Firms in academic incubators are not eligible for the 50 percent credit. Base year employment is defined as the average number of individuals employed full-time by the taxpayer in the city in the year preceding the first calendar year in which the credit is claimed.

Paragraph 3 provides that the maximum amount of tax credits in any year is $3 million, to be allocated among tax payers on a pro rata basis by the New York City Department of Finance.

Paragraph 4 provides that the New York City Department of Finance shall establish rules related to the application process and due dates.

Paragraph 5 provides that such a local law may provide a credit for up to three consecutive years, but may not apply to taxable years starting before January 1,2010 or after January 1, 2013.

Section 2 of the bill provides that the act would take effect immediately.

Statement in support

9 world class research institutions, 26 medical centers, 175 hospitals, and an unparalleled talent pool, New York City has a natural advantage in the bioscience industry. Yet it lags behind other cities, such as Boston and San Diego, in the commercialization of new technologies.

The New York City Biotechnology credit is modeled after, and designed to work with, New York State's Qualified Emerging Technologies Facilities, Operations and Training Credit. Firms will be provided with a refundable credit, for three types of expenses: qualifying expenses related to acquiring research and development property, certain expenses related to training employees, and other research and development expenses. The credit is limited to small firms engaged in research and development that meet New York State standards as qualified emerging technology companies. Such qualified emerging technology companies will be eligible for the credit for up to 3 years (1). The credit will help a young firm equip a lab, train technicians, and fund access to high tech equipment that they do not own.

The credit will differ from New York State's in that it will be focused on growing firms. The allowable expenses and the credit based on those expenses will be the same as for the New York State credit for firms that increase their employment by at least 5 percent, compared to a base year. Those that do not grow will still be eligible for the credit, but at half the rate. Growing firms will have their credit capped at a maximum of $250,000 per year and those that do not make the 5 percent threshold will have a maximum credit of $125,000.

Under this legislation, the total credits for a given year are capped at $3 million. If credits in a given year exceed the cap they will be allocated on a prorated basis by the New York City Department of Finance. The credit would be for three consecutive years starting in January 2010 and ending in December 2012

The credit is part of a policy to create an industry with sufficient size and density that it becomes a good place to make a career in biotech and to locate the kind of ancillary services that the industry needs. This credit works in conjunction with the development of laboratory space at the East River Science Park and in BioBAT at the Brooklyn Army Terminal. These spaces, along with existing facilities, will provide approximately 2 million square feet of laboratory space in the City.

(1) Firms that are located in academic incubators and relocate outside the incubator will be eligible for an additional year of the credit.

Effective date

Immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.